Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Biochemistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Curr Pharm Des. 2018;24(27):3184-3199. doi: 10.2174/1381612824666180828162053.
This systematic review and meta-analysis of randomized controlled trials (RCTs), were performed to determine the effects of curcumin intake on glycemic control and lipid profiles among patients with metabolic syndrome (MetS) and related disorders.
We searched the following databases up until January 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and evaluated for quality of the studies in accordance with the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as standardized mean difference (MDs) with 95% confidence intervals (95% CI).
Twenty-six trials with 1890 participants were included in the current meta-analysis. The findings demonstrated the significant association between curcumin intake and reduced fasting glucose levels (SMD -0.78; 95% CI, -1.20, -0.37; P<0.001), homeostasis model of assessment-estimated insulin resistance (SMD -0.91; 95% CI, -1.52, -0.31; P=0.003) and HbA1c (SMD -0.92; 95% CI, -1.37, -0.47; P<0.001). In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01). However, curcumin intake significantly increased insulin levels (SMD 0.92; 95% CI, 0.06, 1.78; P=0.036). We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).
Overall, curcumin consumption was associated with a significant reduction in fasting glucose, HOMA-IR, HbA1c, triglycerides and total cholesterol levels among patients with MetS and related disorders, but did not affect LDL- and HDL-cholesterol levels.
本系统评价和荟萃分析纳入了随机对照试验（RCTs），旨在确定姜黄素摄入对代谢综合征（MetS）和相关疾病患者血糖控制和血脂谱的影响。
我们检索了以下数据库，截至 2018 年 1 月：MEDLINE、EMBASE、Web of Science 和 Cochrane 对照试验中心注册库。根据 Cochrane 偏倚风险工具，提取相关数据并评估研究质量。使用方差倒数法对数据进行合并，并以标准化均数差（SMD）和 95%置信区间（95%CI）表示。
本荟萃分析纳入了 26 项试验，共 1890 名参与者。结果表明，姜黄素摄入与空腹血糖水平降低（SMD-0.78；95%CI，-1.20，-0.37；P<0.001）、稳态模型评估-估计的胰岛素抵抗（SMD-0.91；95%CI，-1.52，-0.31；P=0.003）和糖化血红蛋白（SMD-0.92；95%CI，-1.37，-0.47；P<0.001）显著相关。此外，姜黄素补充剂与甘油三酯（SMD-1.21；95%CI，-1.78，-0.65；P<0.001）和总胆固醇降低（SMD-0.73；95%CI，-1.32，-0.13；P=0.01）显著相关。然而，姜黄素摄入显著增加了胰岛素水平（SMD 0.92；95%CI，0.06，1.78；P=0.036）。我们发现姜黄素补充剂对 LDL-（SMD-0.52；95%CI，-1.14，0.11；P=0.10）和高密度脂蛋白胆固醇水平（SMD 0.28；95%CI，-0.22，0.77；P=0.27）没有显著影响。
总的来说，姜黄素的摄入与 MetS 和相关疾病患者空腹血糖、HOMA-IR、HbA1c、甘油三酯和总胆固醇水平的显著降低有关，但不影响 LDL-和高密度脂蛋白胆固醇水平。
